心房颤动研究中的 DUTCH 体重控制 (DUTCH-WAIST)
DUTCH 房颤体重控制研究,一项多中心、双盲、随机、平行组、安慰剂对照试验
Quantify the effect of an innovative weight loss management on rhythm control.
研究概览
详细说明
Rationale: Weight reduction promotes reversed atrial remodeling in obese AF patients.
Objective: Quantify the effect of an innovative weight loss management on rhythm control.
Study design: Multi-center, double-blind, randomized, parallel group, placebo-controlled trial of semaglutide 2.4 mg versus placebo.
Study population: Adults with obesity and new onset persistent AF scheduled for electrical cardioversion.
Intervention: semaglutide 2.4 mg subcutaneous (s.c.) once weekly (index) compared to placebo (control), at the background of standard obesity treatment (combined lifestyle intervention) and cardiology follow-up management in both arms.
Main study parameters/endpoints: The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome. The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:
-
Arrhythmic death while using anti-arrhythmic drugs (Vaughn-Williams class I or III)*
-
AF despite pulmonary vein isolation
-
AF despite current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
AF without a pulmonary vein isolation and without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
Sinus rhythm on the 12-lead ECG with the use of a pulmonary vein isolation
-
Sinus rhythm on the 12-lead ECG with current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
Sinus rhythm on the 12-lead ECG without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) and without a pulmonary vein isolation
- When LTFU or death other than anti-arrhythmic death, last known rhythm will be used.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
's-Hertogenbosch、荷兰
- Jeroen Bosch Ziekenhuis
-
Alkmaar、荷兰
- Noordwest Ziekenhuisgroep
-
Amsterdam、荷兰
- Amsterdam UMC
-
Breda、荷兰
- Amphia Ziekenhuis
-
Deventer、荷兰
- Deventer Ziekenhuis
-
Doetinchem、荷兰
- Slingeland Ziekenhuis
-
Eindhoven、荷兰
- Máxima MC
-
Emmen、荷兰
- Treant Zorggroep
-
Goes、荷兰
- Admiraal de Ruyter Ziekenhuis
-
Groningen、荷兰
- Martini Ziekenhuis
-
Groningen、荷兰
- Universitair Medisch Centrum Groningen
-
Haarlem、荷兰
- Spaarne Gasthuis
-
Heerlen、荷兰
- Zuyderland Medisch Centrum
-
Leeuwarden、荷兰
- Frisius MC
-
Maastricht、荷兰
- Maastricht UMC+
-
Roosendaal、荷兰
- Bravis ziekenhuis
-
The Hague、荷兰
- HagaZiekenhuis
-
The Hague、荷兰
- Haaglanden Medisch Centrum
-
Utrecht、荷兰
- Diakonessenhuis
-
-
Gelderland
-
Arnhem、Gelderland、荷兰
- Rijnstate Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -
-
Age ≥ 18
-
Obesity, as defined as:
- BMI ≥ 30 kg/m2, or
- BMI ≥27 kg/m2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)
-
Scheduled ECV
-
Written informed consent
Exclusion Criteria:
- Permanent AF
- Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery
- Current or previous treatment with amiodaron
- HbA1c ≥ 48 mmol/mol, <3 months prior to randomization
- History of diabetes mellitus type 1 or 2
- Prior bariatric surgery
- Use of other anti-obesity medication, <3 months prior to enrollment
- Contra-indication for, or prior use of a GLP1-receptor agonist
- History of chronic pancreatitis or acute pancreatitis <6 months
- Acute coronary syndrome <6 months
- Severe (grade III) valvular disease
- eGFR <30 mL/min/1.73m2
- Heart failure NYHA class III-IV
- Participation in another investigational drug or device study in the past 30 days (registry enrollment is allowed)
- Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy <12 months, as judged by the treating physician.
- Female who is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Intervention
Semaglutide injections + combined lifestyle intervention |
Intervention arm receives semaglutide in addition to combined lifestyle intervention |
|
安慰剂比较:Placebo
Placebo Semaglutide injections + combined lifestyle intervention |
Control arm receives placebo in addition to combined lifestyle intervention |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome
大体时间:At 1 year follow-up
|
The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:
|
At 1 year follow-up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
因 AF 复发而住院的次数。
大体时间:第 0-52 周
|
第 0-52 周
|
|
|
因 AAD 不良事件而计划外去医院就诊的次数。
大体时间:第 0-52 周
|
第 0-52 周
|
|
|
预定的电复律次数。
大体时间:第 0-52 周
|
第 0-52 周
|
|
|
计划外电复律次数。
大体时间:第 0-52 周
|
第 0-52 周
|
|
|
静脉化学复律次数(使用 Vaughan-Williams I 类药物)。
大体时间:第 0-52 周
|
第 0-52 周
|
|
|
计划外心脏复律总数。
大体时间:第 0-52 周
|
第 0-52 周
|
|
|
腰围变化(以厘米为单位)
大体时间:第 0 周和第 52 周
|
第 0 周和第 52 周
|
|
|
重量变化,以 % 和 kg 为单位
大体时间:第 0 周和第 52 周
|
第 0 周和第 52 周
|
|
|
BMI 变化(以 kg/m2 为单位)
大体时间:第 0 周和第 52 周
|
第 0 周和第 52 周
|
|
|
Change in AF related symptoms measured by the modified EHRA classification between the index visit and at 12 months after the index visit.
大体时间:week 0 and 52
|
EHRA: European Heart Rythm Association 1= no symptoms 2a= mild symptoms; Normal dialy activity not affected, symptoms not troublesome to patient 2b= moderate symptoms; Normal daily activity not affected but patient troubled by symptoms 3= severe symptoms; Normal daily activity affected 4= disabling symptoms; Normal daily activity discontinued |
week 0 and 52
|
|
Change in quality of life measured by the EQ-5D-5L between the index visit and at 12 months after the index visit.
大体时间:week 0 and 52
|
Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. LEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/extreme problems |
week 0 and 52
|
合作者和调查者
调查人员
- 首席研究员:Ron Pisters, dr.、Rijnstate Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.